

PerkinElmer introduces industry-first CRISPRi reagents

31 March 2021 | News

CRISPRi Innovations Provide Expanded Experimental Options and Flexibility For Researchers Facilitating Disease & Drug Research

Horizon Discovery, a [PerkinElmer, Inc.](#) company, has announced that its gene editing and modulation portfolio is expanding to include a new family of CRISPR modulation (CRISPRmod) reagents for [CRISPR interference](#) (CRISPRi).

CRISPRi enables scientists to better understand the biological pathways, processes and pathologies of disease by repressing genes at the transcriptional level, ultimately leading to new therapeutic approaches.

The new reagents include the first-ever commercially available [synthetic single guide RNAs for CRISPRi](#), as well as a patent-pending, dCas9-SALL1-SDS3 repressor available in [mRNA](#) and [lentiviral](#) formats.

With these new technologies, researchers will have the flexibility to repress genes in almost all cell lines, over any length of time, and at any scale from single gene readouts to high-throughput studies.

The novel dCas9-SALL1-SDS3 repressor was developed following extensive research and has shown more robust and consistent gene modulation over a longer course of time compared to current-generation CRISPRi products.